Expression of a novel alternatively spliced UCP-2 transcript in osteogenic sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteogenic sarcoma (OGS) frequently exhibits chemoresistance, a mechanism not fully understood.
• Anticancer drugs generate reactive oxygen species; cancer cells may counter this via uncoupling protein 2 (UCP-2).
• UCP-2 can protect tumor cells from chemotherapy, suggesting its role in OGS treatment failure.

Purpose of the Study:

• To investigate the expression of UCP-2 mRNA in osteogenic sarcoma.
• To determine if UCP-2 expression contributes to chemoresistance in OGS.

Main Methods:

• Reverse transcriptase polymerase chain reaction (RT-PCR) was used to quantify UCP-2 mRNA levels.
• RT-PCR compared UCP-2 mRNA in OGS tissues/cell lines versus normal bone.
• Automated nucleotide sequencing identified novel transcripts.

Main Results:

• No induction of standard UCP-2 mRNA was observed in OGS compared to normal bone.
• A novel, alternatively spliced UCP-2 transcript (UCP-2as) was identified in OGS tissues and cell lines.
• UCP-2as, with a 22-nucleotide insertion, introduces an early stop codon, potentially yielding a truncated protein.

Conclusions:

• A novel UCP-2 transcript (UCP-2as) has been identified.
• UCP-2as expression appears specific to osteogenic sarcoma.
• This OGS-specific transcript may confer a survival advantage to tumor cells.